Interestingly, the NDV LX-mIL-7 vaccine displayed strong anti-tumor activity, with mIL-7 expression by the NDV LX strain inducing higher IFN-γ production, greater levels of tumor-infiltrating CD4+ and CD8+ T cells, and stronger cytotoxicity of tumor-specific CD8+ T cells than the NDV LX vaccine (160). This evidence concerns the gene CD8A and neoplasm.